Tuesday, 17 November 2026NewsWorldBusinessTech
Latest

Omalizumab Cuts Alpha-Gal Reaction Severity, Study Finds

Treatment with the allergy drug omalizumab eliminated the need for emergency epinephrine and reduced reaction severity or frequency in 95 percent of participants in a study presented at the annual meeting of the American College of Allergy, Asthma and Immunology.

Alpha-Gal Syndrome Treatment Data

The retrospective cohort analysis evaluated 64 patients with confirmed alpha-gal syndrome who received omalizumab between April 2022 and November 2025, according to data presented at the ACAAI 2026 Annual Scientific Meeting in Phoenix, Arizona.

Prior to beginning therapy, 81 percent of the participants had experienced documented anaphylaxis, and 53 percent had required emergency epinephrine following exposure to mammalian products. The study evaluated patients with a median age of 55 years, spanning a range from 20 to 89 years, and said that 56 percent of the participants were female.

Furthermore, 61 of the 64 participants reported a clinically meaningful reduction in the frequency or severity of their allergic reactions, according to Respiratory Therapy.

External researchers have also evaluated the findings. Pointing out that the findings stemmed from a retrospective evaluation, Supinda Bunyavanich—an allergy and systems biology professor at Mount Sinai Health System located in New York City—called for a complete clinical trial to be performed using the medication.

Bunyavanich said that confirming these results through a prospective investigation would substantially advance the safety and quality of life for people affected by the syndrome.

Patients Reintroduce Mammalian Food with Mild Side Effects

The therapy also enabled some patients to bring mammalian food items back into their diets. Approximately 33 percent of the participants successfully incorporated select red meat options, entire categories of red meat, or alternative mammalian-derived goods back into their daily diets.

Adverse events during the study were infrequent and mostly mild, with joint pain cited as the most common side effect. Two participants stopped treatment because of adverse events.

Lone Star Tick Bites Trigger Widespread Red Meat Allergies

Alpha-gal syndrome is a tick-borne allergy predominantly triggered by the bite of the lone star tick, which transmits a sugar molecule called alpha-gal into the human bloodstream. This can provoke allergic reactions to red meat such as beef, pork, lamb, and certain dairy products. Estimates indicate that between 96,000 and 450,000 individuals in the United States may live with the syndrome.

Omalizumab Cuts Alpha-Gal Reaction Severity, Study Finds
Photo: healio.com

“It used to be something that would be mostly seen by our colleagues who practice in the Southeast or South, but we are increasingly seeing it now,” Bunyavanich, an allergy and systems biology professor at Mount Sinai Health System, said.

Because symptoms often manifest hours after consumption, patients frequently struggle to connect the reaction to the triggering food. Medical experts recommend that individuals take preventive measures against tick exposure when spending time in wooded areas, conducting lawn maintenance, playing golf, or hiking, particularly in regions frequented by deer and small rodents.

Omalizumab Cuts Alpha-Gal Reaction Severity, Study Finds
Photo: Respiratory Therapy

The condition also causes psychological distress. Two-thirds of alpha-gal syndrome patients report experiencing anxiety or depressive disorders, and 63 percent avoid social situations involving food. Specialists say these statistics show that routine screening protocols must include integrated mental health support.

Patients considering treatment strategies or experiencing symptoms of food-related allergies should consult qualified medical professionals for guidance tailored to their individual medical history.

Pediatric Severe Asthma : Which Biologics Treatment for Which Patients? — American Thoracic Society